Single-atom nanozymes shines diagnostics of gastrointestinal diseases.

Publisher: BioMed Central Country of Publication: England NLM ID: 101152208 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-3155 (Electronic) Linking ISSN: 14773155 NLM ISO Abbreviation: J Nanobiotechnology Subsets: MEDLINE

Original Publication: London : BioMed Central, 2003-

Gastrointestinal Diseases* ; Nanostructures*/chemistry; Humans ; Animals ; Enzymes/chemistry ; Enzymes/metabolism ; Superoxide Dismutase/chemistry ; Superoxide Dismutase/metabolism ; Catalase/chemistry ; Catalase/metabolism ; Catalysis ; Glutathione Peroxidase/metabolism

Various clinical symptoms of digestive system, such as infectious, inflammatory, and malignant disorders, have a profound impact on the quality of life and overall health of patients. Therefore, the chase for more potent medicines is both highly significant and urgent. Nanozymes, a novel class of nanomaterials, amalgamate the biological properties of nanomaterials with the catalytic activity of enzymes, and have been engineered for various biomedical applications, including complex gastrointestinal diseases (GI). Particularly, because of their distinctive metal coordination structure and ability to maximize atom use efficiency, single-atom nanozymes (SAzymes) with atomically scattered metal centers are becoming a more viable substitute for natural enzymes. Traditional nanozyme design strategies are no longer able to meet the current requirements for efficient and diverse SAzymes design due to the diversification and complexity of preparation processes. As a result, this review emphasizes the design concept and the synthesis strategy of SAzymes, and corresponding bioenzyme-like activities, such as superoxide dismutase (SOD), peroxidase (POD), oxidase (OXD), catalase (CAT), and glutathione peroxidase (GPx). Then the various application of SAzymes in GI illnesses are summarized, which should encourage further research into nanozymes to achieve better application characteristics.
(© 2024. The Author(s).)

Angew Chem Int Ed Engl. 2021 Feb 15;60(7):3469-3474. (PMID: 33118263)
Nano Today. 2021 Oct;40:101243. (PMID: 34249143)
Sci Adv. 2019 May 03;5(5):eaav5490. (PMID: 31058221)
Angew Chem Int Ed Engl. 2021 Apr 26;60(18):9959-9963. (PMID: 33599380)
Small. 2019 Nov;15(48):e1901485. (PMID: 31111647)
Nat Commun. 2019 Nov 15;10(1):5181. (PMID: 31729358)
ACS Appl Mater Interfaces. 2021 Sep 29;13(38):45269-45278. (PMID: 34520159)
Nanoscale Adv. 2020 Feb 27;2(4):1583-1589. (PMID: 36132318)
Chem Soc Rev. 2023 Oct 30;52(21):7504-7523. (PMID: 37814831)
J Colloid Interface Sci. 2022 Jul 15;618:68-77. (PMID: 35334363)
Signal Transduct Target Ther. 2023 Jul 21;8(1):277. (PMID: 37474504)
J Am Chem Soc. 2021 Nov 10;143(44):18643-18651. (PMID: 34726407)
Adv Mater. 2022 Aug;34(31):e2202898. (PMID: 35729082)
ACS Nano. 2023 Jul 25;17(14):13062-13080. (PMID: 37399457)
Small. 2019 Oct;15(43):e1903108. (PMID: 31482681)
Adv Mater. 2020 Sep;32(36):e2002246. (PMID: 32705751)
Adv Mater. 2023 Nov;35(44):e2303567. (PMID: 37466394)
CA Cancer J Clin. 2023 May-Jun;73(3):286-319. (PMID: 36495087)
Lancet. 2019 Oct 19;394(10207):1467-1480. (PMID: 31631858)
Nat Commun. 2020 Jan 17;11(1):357. (PMID: 31953423)
Anal Chim Acta. 2020 Sep 1;1128:72-79. (PMID: 32825914)
Biomaterials. 2022 Feb;281:121325. (PMID: 34953332)
Adv Mater. 2023 Mar;35(9):e2208512. (PMID: 36373624)
ACS Nano. 2023 Dec 12;17(23):24404-24416. (PMID: 38039189)
Adv Mater. 2023 Dec;35(49):e2306748. (PMID: 37689996)
Angew Chem Int Ed Engl. 2022 Nov 7;61(45):e202212542. (PMID: 36093883)
Redox Biol. 2017 Apr;11:240-253. (PMID: 28012439)
Adv Mater. 2024 Mar;36(10):e2211724. (PMID: 36773312)
J Colloid Interface Sci. 2023 Dec 15;652(Pt B):1712-1725. (PMID: 37672974)
CA Cancer J Clin. 2022 Jan;72(1):7-33. (PMID: 35020204)
Biosens Bioelectron. 2019 Oct 1;142:111495. (PMID: 31310943)
Talanta. 2023 Dec 1;265:124870. (PMID: 37418955)
J Colloid Interface Sci. 2019 Feb 1;535:425-435. (PMID: 30317083)
Hepatology. 2020 Feb;71(2):522-538. (PMID: 31228214)
J Am Chem Soc. 2018 Jan 24;140(3):984-992. (PMID: 29275637)
Adv Mater. 2022 Apr;34(15):e2109568. (PMID: 35151235)
Adv Mater. 2022 Apr;34(16):e2200255. (PMID: 35132711)
Adv Mater. 2024 Mar;36(10):e2300951. (PMID: 37310697)
Nat Commun. 2021 Jan 7;12(1):114. (PMID: 33414464)
Colloids Surf B Biointerfaces. 2020 Nov;195:111252. (PMID: 32679446)
J Colloid Interface Sci. 2023 Apr 15;636:568-576. (PMID: 36669450)
ACS Nano. 2021 Feb 23;15(2):2005-2037. (PMID: 33566564)
Angew Chem Int Ed Engl. 2021 Jun 1;60(23):12971-12979. (PMID: 33772996)
Gastroenterology. 1948 Jun;10(6):923-38. (PMID: 18867637)
Nano Lett. 2015 Jan 14;15(1):403-9. (PMID: 25539021)
Adv Mater. 2019 May;31(19):e1900401. (PMID: 30920710)
Chem Soc Rev. 2023 Feb 20;52(4):1382-1427. (PMID: 36723190)
Chem Soc Rev. 2023 Oct 16;52(20):7071-7136. (PMID: 37755573)
ACS Appl Mater Interfaces. 2023 Feb 8;15(5):6473-6485. (PMID: 36718115)
Adv Sci (Weinh). 2024 Mar;11(11):e2308439. (PMID: 38227382)
Adv Sci (Weinh). 2023 Oct;10(30):e2302703. (PMID: 37697645)
Adv Mater. 2023 Nov;35(46):e2305077. (PMID: 37497609)
Adv Mater. 2022 Apr;34(15):e2107088. (PMID: 35102632)
Signal Transduct Target Ther. 2022 Mar 28;7(1):86. (PMID: 35342192)
Anal Chem. 2019 Sep 17;91(18):11994-11999. (PMID: 31436084)
Am J Gastroenterol. 2013 Sep;108(9):1400-15; 1416. (PMID: 23896955)
Angew Chem Int Ed Engl. 2021 Apr 19;60(17):9480-9488. (PMID: 33543825)
Small. 2023 Jul;19(30):e2300750. (PMID: 37058076)
Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):690-704. (PMID: 31554963)
CA Cancer J Clin. 2017 Jul 8;67(4):273-289. (PMID: 28586094)
Acta Pharm Sin B. 2023 Dec;13(12):5030-5047. (PMID: 38045041)
Small. 2024 Feb;20(8):e2306656. (PMID: 37817351)
ACS Appl Mater Interfaces. 2020 Jun 10;12(23):25625-25632. (PMID: 32383848)
J Nanobiotechnology. 2023 Nov 23;21(1):443. (PMID: 37996911)
Chem Soc Rev. 2019 Feb 18;48(4):1004-1076. (PMID: 30534770)
Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):483. (PMID: 37414878)
Biosens Bioelectron. 2023 Jan 15;220:114893. (PMID: 36423391)
Adv Mater. 2020 Mar;32(11):e1906972. (PMID: 31984566)
Angew Chem Int Ed Engl. 2023 Mar 20;62(13):e202218661. (PMID: 36719177)
Adv Mater. 2020 Dec;32(48):e2005912. (PMID: 33124716)
Angew Chem Int Ed Engl. 2021 Dec 1;60(49):25701-25707. (PMID: 34477299)
Theranostics. 2023 Apr 29;13(8):2721-2733. (PMID: 37215581)
Biomater Sci. 2023 Nov 21;11(23):7616-7622. (PMID: 37828832)
J Am Chem Soc. 2018 Mar 21;140(11):3876-3879. (PMID: 29518310)
ACS Nano. 2019 Oct 22;13(10):11552-11560. (PMID: 31553878)
Anal Chem. 2021 Sep 21;93(37):12758-12766. (PMID: 34476936)
Small. 2023 Aug;19(31):e2300883. (PMID: 37029573)
RSC Adv. 2019 Feb 25;9(12):6460-6481. (PMID: 35518468)
Acc Chem Res. 2022 Dec 20;55(24):3752-3766. (PMID: 36454588)
ACS Appl Mater Interfaces. 2019 Dec 11;11(49):45416-45426. (PMID: 31713410)
Biomaterials. 2023 Jun;297:122109. (PMID: 37058901)
Acta Biomater. 2023 Mar 1;158:686-697. (PMID: 36623782)
ACS Nano. 2022 Jan 25;16(1):855-868. (PMID: 35025200)
ACS Nano. 2022 Dec 27;16(12):20851-20864. (PMID: 36458840)
J Colloid Interface Sci. 2024 May;661:482-492. (PMID: 38308888)
Angew Chem Int Ed Engl. 2019 Apr 1;58(15):4911-4916. (PMID: 30697885)
Small. 2019 Aug;15(31):e1901834. (PMID: 31207096)
J Am Chem Soc. 2020 Jan 8;142(1):70-74. (PMID: 31840513)
Adv Sci (Weinh). 2022 Feb;9(5):e2103977. (PMID: 34951150)
Angew Chem Int Ed Engl. 2020 Mar 23;59(13):5108-5115. (PMID: 31960567)
Nanoscale Adv. 2021 Nov 17;4(1):190-199. (PMID: 36132964)
Nat Commun. 2023 Nov 6;14(1):7127. (PMID: 37949885)
Nat Rev Gastroenterol Hepatol. 2017 Oct;14(10):573-584. (PMID: 28743984)
Adv Sci (Weinh). 2023 Jun;10(18):e2207342. (PMID: 37096842)
Nat Rev Gastroenterol Hepatol. 2021 Jul;18(7):493-502. (PMID: 34002083)
Small. 2023 Sep;19(37):e2207510. (PMID: 37231552)
J Nanobiotechnology. 2023 Jan 19;21(1):21. (PMID: 36658555)
Anal Chim Acta. 2021 Oct 2;1180:338856. (PMID: 34538322)
Angew Chem Int Ed Engl. 2022 Aug 26;61(35):e202205978. (PMID: 35679132)
Adv Colloid Interface Sci. 2024 Jan;323:103050. (PMID: 38086152)
Anal Chem. 2020 Feb 18;92(4):3373-3379. (PMID: 31941278)
Small. 2022 Sep;18(37):e2203001. (PMID: 35986440)
Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):377. (PMID: 19575019)
ACS Appl Mater Interfaces. 2020 Mar 11;12(10):11616-11624. (PMID: 32068379)
J Am Chem Soc. 2020 Nov 11;142(45):19259-19267. (PMID: 33119292)
Talanta. 2020 Feb 1;208:120375. (PMID: 31816679)
Bioact Mater. 2021 Apr 30;6(12):4389-4401. (PMID: 33997515)
Chem Commun (Camb). 2018 Dec 20;55(2):159-162. (PMID: 30465670)
J Am Chem Soc. 2020 Sep 9;142(36):15569-15574. (PMID: 32790301)
Adv Mater. 2022 Nov;34(44):e2205674. (PMID: 36073657)
Nanomicro Lett. 2020 Oct 27;13(1):7. (PMID: 34138193)
Sci Adv. 2020 Jul 17;6(29):eabb2695. (PMID: 32832640)
ACS Appl Mater Interfaces. 2023 Dec 6;15(48):55466-55485. (PMID: 37991753)
Chem Commun (Camb). 2019 Nov 28;55(96):14534-14537. (PMID: 31740902)
Int J Nanomedicine. 2023 Feb 21;18:933-948. (PMID: 36852185)
J Nanobiotechnology. 2023 Dec 21;21(1):500. (PMID: 38129928)

2024C03048 Zhejiang Province's 2024 Key R&D Plan Project; GZY-ZJ-KJ-24093 Zhejiang Provincial Traditional Chinese Medicine Science and Technology Project; 202004A14 Hangzhou Science and Technology Commission; OO20190001 Construction Fund of Medical Key Disciplines of Hangzhou

Keywords: Antibacterial; Bioassay; Cancer therapy; Catalytic regulation; Gastrointestinal diseases; Single-atom nanozymes

0 (Enzymes)
EC 1.15.1.1 (Superoxide Dismutase)
EC 1.11.1.6 (Catalase)
EC 1.11.1.9 (Glutathione Peroxidase)

Date Created: 20240525 Date Completed: 20240525 Latest Revision: 20240613

20240614

PMC11127409

10.1186/s12951-024-02569-3

38796465